Mebendazole is a broad-spectrum microtubule-disrupting anthelmintic that is active against adult or larval cestodes, and human intestinal nematodes [1][2]. Mebendazole had good potency against Giardia isolates with IC50 for a 24-h was 0.19 μM and for a 4-h exposure was 2.7 μM, respectively. And inhibition of Giardia growth in vitro was maintained beyond 72 to 96 h [2].

Mebendazole is a broad-spectrum anthelmintic and a tubulin-disrupting agent. Mebendazole inhibited melanoma growth with an average IC50 of 0.32 μmol/L and induced apoptosis through the intrinsic and extrinsic mitochondrial pathways. In melan-a, M-14, and SK-Mel-19 cells, Mebendazole caused overall microtubular network disarray. In M-14 and SK-Mel-19 melanoma cells, Mebendazole led to Bcl-2 phosphorylation, which then promoted melanoma apoptosis [3]. In human lung cancer cell lines, Mebendazole arrested cells at the G2-M phase before the onset of apoptosis [4]. Also, Mebendazole potently inhibited Hh signaling and slowed the growth of Hh-driven human medulloblastoma cells [6]. Additionally, mebendazole stabilized the transcriptional activator HIF-1α and its downstream targets, preventing oxidative neuronal death in primary neurons [7].

In nu/nu mice bearing human tumor xenografts, Mebendazole inhibited tumor growth and significantly reduced the number and size of tumors [4][5].